Basic Information


GTO ID GTC2794
Trial ID NCT05057715
Disease Ovarian Cancer | Pancreatic Cancer
Altered gene MESO
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment huCAR-T-meso cells
Co-treatment VCN-01
Generation2nd
PhasePhase1
Recruitment statusRecruiting
TitleHuCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Year2021
CountryUnited States
Company sponsorUniversity of Pennsylvania
Other ID(s)UPCC# 03821, IND #27590
Vector information
Vectorlentivirus
ConstructscFv-4-1BB-CD3ζ
Transgene/Inserted geneanti-mesothelin ‘M5’ ScFv; 4-1BB

Clinical Result

Cohort 1
Administration route intravenous infusion
Dosage 5E7 cells, single infusion
Donor type Autologous
Pts 12
Age Adult, Older_Adult
References : 671 Phase 1 trial of human chimeric antigen receptor modified T cells (huCART-meso) administered in combination with oncolytic virus VCN-01 in patients with pancreatic and ovarian cancer

Relationship Graph

Overview of Knowledge Graph